today announced that it reacquired the rights to IMCIVREE ® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing ...

In 11/2020 the FDA initially approved IMCIVREE (setmelanotide) for chronic weight management in certain patients with obesity due to the following specific genetic conditions: proopiomelanocortin ...

"Based on the unmet need and severity of Prader-Willi syndrome and learnings from our initial study, we plan to initiate an ...

Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...

While it thinks the Imcivree launch continues to progress well, BofA believes the current valuation bakes in value for the current launch trajectory. The firm looks to upcoming catalysts in 2025 ...

“Rhythm delivered solid IMCIVREE global sales growth in the fourth quarter and is poised to drive continued growth in 2025,” said David Meeker, M.D., Chairman, Chief Executive Officer and ...

Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million -- -- On track to report ...